Work

A placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy (S13.003)

Year: 2017

Type: article

Source: Neurology

DOI: 10.1212/wnl.88.16_supplement.s13.003

Authors: Christopher Grunseich, Ram Miller, Therese Swan, David Glass, Mohamed El Mouelhi, Mara Fornaro, Olivier Petricoul, Igor Vostiar, Ronenn Roubenoff, Matthew Meriggioli, John Vissing, Gianni Soraru, Tahseen Mozaffar, Albert Ludolph, John Kissel, Kenneth Fischbeck

Institutions: National Institutes of Health, National Institute of Neurological Disorders and Stroke, Novartis (Switzerland), Novartis Institutes for BioMedical Research, Rush University Medical Center, University of Padua, University of California, Irvine, Universität Ulm, The Ohio State University Wexner Medical Center, The Ohio State University

Language: English

Topic: Genetic Neurodegenerative Diseases

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2899326598

FWCI:

Cites:

Cited by:

Related to: 10